MARKET

TRIB

TRIB

Trinity Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.180
-0.150
-6.44%
Closed 19:57 09/24 EDT
OPEN
2.260
PREV CLOSE
2.330
HIGH
2.354
LOW
2.170
VOLUME
95.59K
TURNOVER
--
52 WEEK HIGH
6.82
52 WEEK LOW
1.750
MARKET CAP
45.57M
P/E (TTM)
-30.2778
1D
5D
1M
3M
1Y
5Y
Sidoti - Fall Virtual Small Cap Investor Conference
Presentation Times and Weblinks Released for Over 130 Presenting CompaniesWednesday and Thursday, September 22 - 23, 2021NEW YORK, NY / ACCESSWIRE / September 21, 2021 / Sidoti & Company, LLC proudly releases the presentation schedule, with weblink click-t...
ACCESSWIRE · 5d ago
48 Biggest Movers From Yesterday
Gainers
Benzinga · 09/10 09:16
35 Stocks Moving In Thursday's Mid-Day Session
Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE: OPAD) surged 35.3% to $15.62. Torrid Holdings Inc. (NYSE: CURV) shares gained 2...
Benzinga · 09/09 16:01
ProQR Therapeutics, Centessa Pharmaceuticals leads healthcare gainers; Humanigen, Invacare among major losers
Gainers: ProQR Therapeutics (NASDAQ:PRQR) +22%, Centessa Pharmaceuticals (NASDAQ:CNTA) +22%, Kiromic BioPharma (NASDAQ:KRBP) +19%, Trinity Biotech (NASDAQ:TRIB) +16%, Enveric Biosciences (NASDAQ:ENVB) +14%. Losers: Humanigen (NASDAQ:HGEN) -54%, Invacare (N...
Seekingalpha · 09/09 14:59
Trinity Biotech Q2 Results Rise; Shares Rise Amid Heavy Trading
MT Newswires · 09/09 14:04
Trinity Biotech Q2 EPS $0.20 Beats $0.07 Estimate, Sales $25.84M Beat $25.00M Estimate
Trinity Biotech (NASDAQ:TRIB) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.07 by 185.71 percent. This is a 1900 percent increase over earnings of $0.01 per share from the
Benzinga · 09/09 13:27
Trinity Biotech Announces Results for Q2, 2021
DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30...
GlobeNewswire · 09/09 12:45
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TRIB. Analyze the recent business situations of Trinity Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TRIB stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 7.18M
% Owned: 34.33%
Shares Outstanding: 20.90M
TypeInstitutionsShares
Increased
9
567.67K
New
3
23.60K
Decreased
6
169.96K
Sold Out
8
160.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chairman/Director
Ronan O'Caoimh
Chief Financial Officer/Executive Director/Secretary
John Gillard
Executive Vice President
Fernando Devia
Senior Vice President
Sanjiv Suri
Chief Accounting Officer
Simon Dunne
Chief Information Officer
Eibhlin Kelly
Executive Director
James Walsh
Other
Terence Dunne
Director
Kevin Tansley
Non-Executive Director
Clinton Severson
Non-Executive Independent Director
James Merselis
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.22
06/05/2015
--
Dividend USD 0.22
06/06/2014
05/31/2013
Dividend USD 0.2
06/06/2013
06/05/2012
Dividend USD 0.15
06/06/2012
--
Dividend USD 0.1
06/07/2011
  • All
  • Financials
  • Insiders
More
About TRIB
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Webull offers kinds of Trinity Biotech plc (ADR) stock information, including NASDAQ:TRIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRIB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRIB stock methods without spending real money on the virtual paper trading platform.